NCT05549661View on ClinicalTrials.gov

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

June 1, 2027

Study Completion Date

December 1, 2027

Conditions
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm, Not Otherwise SpecifiedRecurrent Atypical Chronic Myeloid LeukemiaRecurrent Myelodysplastic/Myeloproliferative NeoplasmRefractory Myelodysplastic/Myeloproliferative Neoplasm
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration and biopsy

DRUG

Onvansertib

Given PO

PROCEDURE

Ultrasound Imaging

Undergo ultrasound imaging

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER